Phosphodiesterases (PDEs) The selective targeting of phosphodiesterases type 4 (PDE4) has been actively pursued as a novel therapeutic approach in the treatment of respiratory diseases associated with inflammatory processes such as asthma and chronic obstructive pulmonary disease (COPD). The rationale for their use in respiratory disease is based on the clinical efficacy of non-selective PDE inhibitors such as theophylline, the detection of PDE4 in many of the cells involved in these diseases and the emergence of positive results from a number of pharmacological studies and clinical trials currently evaluating the efficacy of selective PDE4 inhibitors in respiratory diseases (Barnette 1999 , Spina 2000 . PDE4 represent the major class of PDE expressed in human inflammatory cells (Wang et al. 1999) and in particular in macrophages, eosinophils and neutrophils, the main cell types present in the lungs of asthmatic and COPD patients.
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PDE4 are members of the phosphodiesterase (PDE) superfamily of enzymes, which comprises at least 11 members hydrolyzing cyclic AMP (adenosine 3',5'-cyclic monophosphate) and/or cyclic GMP (guanosine 3',5'-cyclic monophosphate) (Houslay et al. 1998 , Conti & Jin 1999 , Giembycz 2000 . In the case of PDE4, there are four gene products and multiple splice variants resulting in a variety of PDE4 isoforms. PDE4 selectively catalyse the hydrolysis of cAMP and the anti-inflammatory effects of selective PDE4 inhibitors were supposed to result of the reduction of cAMP hydrolysis. However, some recent studies have demonstrated that PDE4 could also act through cAMP-independent mechanisms. Indeed, we have observed that PDE4 inhibitors triggered a cAMP-independent inhibition of fMLP-induced O 2. -release from bronchoalveolar lavage cells of rats exposed to lipopolysaccharide . We also showed that the inhibitory effect of PDE4 inhibitors on O 2. -production is mediated by the activation of p44/42 MAPK and that PDE4 inhibit p44/42 MAPK by a direct interaction ). This study allowed us to identify a novel mechanism involving MAPK in the pathway connecting PDE4 to fMLP-induced O 2. -generation in neutrophils.
Therapeutical potential of selective PDE4 inhibitors
During last decade, numerous studies have demonstrated the modulation of inflammatory cells activation by selective PDE4 inhibitors. It is now established that an elevation of cAMP is able to inhibit some of inflammatory processes. The use of PDE4 inhibitors, preventing cAMP hydrolysis, appears obvious to treat inflammatory diseases like asthma and COPD.
Rolipram, a first generation selective PDE4 inhibitor, has been shown to decrease influx of inflammatory cells to the site of inflammation induced by various stimuli (Lagente et al. 1994 , Teixeira et al. 1997 . In vitro exposure of rat eosinophils to rolipram decreases eosinophil migration evoked by either PAF or LTB 4 (Alves et al. 1996) . It has also been demonstrated that salbutamol it-self did not modify eosinophil migration evoked by either PAF or eotaxin in vitro but clearly improved the inhibitory effect of rolipram suggesting an involvement of the cAMP pathway in the eosinophil chemotaxis (Silva et al. 2001) . In a guinea pig model of lipopolysaccharide (LPS)-induced lung neutrophilia, rolipram was able to inhibit 63% of neutrophil infiltration (Toward & Broadley 2001) , could completely abolish neutrophil influx induced by antigen challenge in Brown Norway rats (Howell et al. 1995) and could decrease by 75% LPS-induced lung neutrophilia in mice (Miotla et al. 1998) . In a recent study, we compared the effect of a selective PDE4 inhibitor, cilomilast and a glucocorticoid, dexamethasone on cigarette smoke and LPS induce airway neutrophilia (Leclerc et al. 2004) . As expected both cilomilast and dexamethasone were able to dosedependently block LPS-induced neutrophilia. Cilomilast was also able to block neutrophilia induced by cigarette smoke with the same efficacy. However, dexamethasone treatment at the same dose was unable to block neutrophilia induced by cigarette smoke exposure (Leclerc et al. 2004) . Furthermore, the selective PDE4 inhibitor, CI-1044 given orally (30 mg/kg/day), significantly inhibited the development of emphysema by 89%, 24 weeks following cigarette smoke exposure in mice (Pruniaux et al. 2003) and support the use of PDE4 in-hibitors as a new COPD therapy.
One of the major anti-inflammatory effect of PDE4 inhibitors is their ability to down-regulate cytokine production both in vivo and in vitro. In vivo, some studies report the ability of PDE4 inhibitors to reduce TNF-α release in the blood or in BAL fluids of various species (Griswold et al. 1998 , Corbel et al. 2002a ). In vitro, several selective PDE4 inhibitors, including rolipram and cilomilast, have been previously shown to inhibit the release of TNF-α by LPS-stimulated murine mononuclear cells, human monocytes or whole blood from healthy individuals (Souness et al. 1996 , Gonçalves de Moraes et al. 1998 . Furthermore, we recently showed that rolipram and cilomilast inhibit LPS-stimulated TNF-α production in the whole blood from patients with COPD (Ouaged et al. 2004 ). The novel PDE4 inhibitor CI-1044 which induced a potent inhibition of PDE4 activity both in vitro and in vivo (Burnouf et al. 2000) , is 2 to 10 times more potent than rolipram and cilomilast respectively, to inhibit LPSstimulated TNF-α release in the human whole blood from patients with COPD.
Nevertheless, the ability of PDE4 inhibitors to prevent or modulate the airway remodelling remains a relatively unexplored area. Matrix metalloproteinases (MMPs) play an important role in the proteolytic degradation of the extracellular matrix (ECM), both in physiological processes and during pathological events (Corbel et al. 2002b ). The most accepted theory for the pathogenesis of COPD, which includes emphysema and/or chronic bronchitis, and idiopathic pulmonary fibrosis (IPF), involves deteriorated lung homeostasis. This abnormal remodelling results in a net increase in deposited ECM and collagen content in lungs, resulting from MMPs/TIMPs imbalance (Jeffery 2001) . These lung disorders are also characterized by a striking fibroblast/myofibroblast proliferation and activation, which increase the production of matrix-degrading enzymes (Crouch 1990 , Segura-Valdez et al. 2000 . Furthermore, local over-expression of cytokines and/or growth factor stimulates resident lung fibroblasts to synthesize increased amount of collagen and different MMPs such as collagenase-1 (MMP-1), gelatinases A and B (MMP-2 and MMP-9) (Sasaki et al. 2000 , Zhu et al. 2001 .
However, we reported that the selective PDE4 inhibitor, piclamilast reduced antigen challenge induced-cell recruitment in airways of sensitized mice, but also diminished gelatinase B MMP -9 (Belleguic et al. 2000) . We have also demonstrated that piclamilast (RP 73-401), reduced MMP-9 activity and TGF-β1 release during acute lung injury in mice, suggesting that PDE4 inhibitors might modulate tissue remodelling associated with lung injury (Corbel et al. 2002a ). Furthermore recent studies have shown that two selective PDE4 inhibitors, cilomilast and rolipram, inhibited fibroblast chemotaxis and fibroblastmediated collagen gel contraction. It has also been demonstrated that cilomilast might inhibit the TNF-α-induced release of both MMP-1 and MMP-9 from HFL-1 (Kohyama et al. 2002a,b) . Fibroblasts cultured with PMA or TNF-α released increased amounts of pro-MMP-1, whereas TGF-β1 had no effect (Martin-Chouly et al. 2004 ). Incubation with CI-1044 or cilomilast significantly prevented the TNF-α increase in pro-MMP-1. These results suggest that PDE4 inhibitors are effective in inhibiting the pro-MMP-2 and pro-MMP-1 secretion induced by TNF-α and might underline a potential therapeutic benefit of selective PDE4 inhibitors in lung diseases associated with abnormal tissue remodelling (Martin-Chouly et al. 2004 ).
Clinical experience with selective PDE4 inhibitors
The most advanced PDE4 inhibitors in clinical development i.e., cilomilast and roflumilast have demonstrated encouraging efficacy to date. Cilomilast has been shown to improve both pulmonary function and symptoms of COPD in 424 patients with moderate-to-severe disease, producing significant improvements in FEV1, FVC and PEFR versus placebo over 6 weeks ). In addition, consistent improvements in patient quality of life approaching that defined as clinically relevant were observed compared with placebo (Giembycz 2001 ). In addition, cilomilast significantly reduces the risk of exacerbations and provides sustained improvements in lung function over 6 months in patients with mild-to moderate disease . Interestingly, the improvements in lung function observed with cilomilast are independent of smoking status (Zhu et al. 2002) . More recently, the anti-inflammatory effects of cilomilast observed in preclinical studies have been confirmed in a small, randomized, placebo-controlled trial of 59 patients with COPD (Gamble et al. 2003) . After 12 weeks of cilomilast therapy, bronchial biopsies taken from treated patients indicated that cilomilast significantly reduces levels of inflammatory markers, i.e. CD8 T cells and CD68 macrophages (Gamble et al. 2003) . Roflumilast has also shown encouraging efficacy in patients with COPD, with significant improvements observed in FEV1 and PEFR versus baseline (Leitchl et al. 2002) .
A major benefit of cilomilast and roflumilast is their superior safety and tolerability profile versus theophylline and the first generation PDE4 inhibitors. Indeed, theophylline is associated with serious cardiovascular and central nervous system side effects, even at therapeutic doses. These effects are generally attributed to nonselective inhibition of PDEs, as well as concomitant adenosine receptor antagonism and include tachycardia and serious arrhythmias, focal and generalized seizures, and coma (Barnes 2003) . When the first generation PDE4 inhibitors were developed, it was hypothesized that these compounds could present less side effects than theophylline, due to their selectivity for PDE4. However, these agents were associated with a number of adverse events, including nausea, vomiting and gastric acid secretion, which limit their clinical use (Barnette 1999) . In contrast, second generation PDE4 inhibitors have an improved therapeutic ratio. Cilomilast has proven safe and well tolerated at doses of up to 15 mg in both short-and long-term dosing trials, with a moderate incidence of adverse events which appears in more than 5% of patients (Giembycz 2001 . The most common adverse experience was nausea, which arose most often in the cilomilast 10 and 15 mg treatment groups. Nausea arose most commonly within a few days of starting treatment and was generally mild or moderate and selflimiting. Vomiting was infrequent in all treatment groups. The most common serious adverse event was exacerbation of COPD, which was responsible for all three cases in the placebo group. There was no pattern or trend for any serious adverse reactions associated with cilomilast.
Strategies to avoid side-effects induced by oral PDE4 inhibitors
The therapeutic promise of PDE4 inhibitors has been tempered by their significant side-effects, particularly nausea and emesis. Thus the broad goal of drug development has been to improve the side-effect profile of PDE4 inhibitors while maintaining or improving efficacy. One strategy that has been pursued with some success is based upon the observation that PDE4 enzymes exist in both low-and high-affinity rolipram-binding conformations (Torphy et al. 1992a , Jacobitz et al. 1996 . Although inhibition of the low-affinity rolipram-binding conformation correlates with inhibition of cyclic AMP hydrolysis and with inhibition of several inflammatory cell functions, inhibition of high-affinity rolipram binding appears to correlate with the production of certain side effects (Barnette et al. 1996 , Souness et al. 1997 ). This has been demonstrated with a selective PDE4 inhibitor derived from 9-benzyladenine (NCS 613), which elicited anti-inflammatory properties . The fact that NCS 613 did not stimulate the gastric acid secretion suggest that this compound structurally unrelated to rolipram, may produce fewer gastrointestinal side effects .
Compounds with relative selectivity for the lowaffinity form of the enzyme would therefore be expected to display better therapeutic ratios than rolipram, which is selective for the high affinity conformation (Barnette et al. 1996) .
A second promising strategy is the development of subtype selective PDE4 Inhibitors. Indeed, type 4 phosphodiesterases consist of 4 subtypes A, B, C and D, encoded by 4 genes (Conti & Jin 1999) , which are alternatively spliced in different variants 1, 2, 3 (2, 3, 4, 5, 6) . Two different structures of these variants can be distinguished, short forms (65-75 kDa) and long forms . The difference between short and long forms lies in the N-terminal region, at the level of UCR1 and UCR2 (upstream conserved regions): short forms are truncated at UCR2 and long forms have both UCR1 and UCR2 (Bolger et al. 1997) . The different PDE4 subtypes are differently expressed depending on the tissue. PDE4A is expressed in all tissues except in neutrophils (Wang et al. 1999) , PDE4B is widely expressed and is the pre-dominant PDE4 subtype in monocytes and neutrophils (Wang et al. 1999) , but lacks in cortex and epithelial cells (Jin et al. 1998) , PDE4C is absent from circulating inflammatory cells, cortex and hippocampus and has been detected in lung and testis (Obernolte et al. 1997 , Manning et al. 1999 , Martin-Chouly et al. 2004 ) and PDE4D is particularly active in lung, cortex, cerebellum and T cells , Jin et al. 1998 . The up-regulations of the PDE4B subtype in response to pro-inflammatory agents suggest that PDE4B could be particularly involved in inflammatory processes. However, by screening a large number of PDE4 inhibitors against the recombinant human enzyme, it has been able to identify a few selective subtype inhibitors (Manning et al. 1999 ). The results obtained using these kinds of compounds suggest that PDE4A and or PDE4B may play the major role in regulating LPS-induced TNF-α release and T-cell proliferation but do not rule out PDE4D as an important mediator of other activities in mononuclear leukocytes and other immune and inflammatory cells (Manning et al. 1999 . Using an in vitro model of DMSO-treated HL60 cells, we found a change of PDE4 subtype profile during differentiation (Jacob et al. 2002) . PDE4B was the predominant isoenzyme, PDE4D was down-regulated and PDE4A was no longer detectable. Additionally, the more NADPH oxidase was activated by PMA, the less PDE4A was expressed, suggesting that NADPH oxidase activity could be used as a surrogate marker of PDE4A down-regulation. Rolipram and Ariflo (cilomilast), two selective PDE4 inhibitors, dose-dependently inhibited receptor-coupled activation of superoxide. These results suggest that PDE4B is the main subtype involved in regulating superoxide induced by immune complex activation. Furthermore, these cells, expressing almost exclusively PDE4B subtype, could be useful to identify selective PDE4B inhibitors (Jacob et al. 2002) .
More recently, using mice deficient in either the PDE4B or PDE4D gene, Robichaud and colleagues (2002) provide evidence that emesis resulting from administration of PDE4 inhibitors is due to the selective inhibition of PDE4D. This is an unfortunate finding because the most clinically advanced PDE4 inhibitors are selective for PDE4D.
Conclusion
Type 4 phosphodiesterases have the potency to modulate a large range of inflammatory mediators release through cAMP-dependent and cAMP-independent mechanisms. Several times, PDE4B subtype has been shown to be particularly involved in these inflammatory processes, indicating that this PDE4B subtype could be a good target for new anti-inflammatory compounds with less side effects than already known non-subtype selective PDE4 inhibitors. These side effects, mainly nausea and emesis, considerably limit the use of these drugs. PDE4 inhibitors are very promising compounds, which could bring new alternatives for the treatment of chronic diseases like asthma, chronic obstructive pulmonary disease and atopic dermatitis.
